We are live on ! Find out more
ORKA

Oruka Therapeutics
ORKA

81 hedge funds and large institutions have $386M invested in Oruka Therapeutics in 2025 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 27 increasing their positions, 14 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 14

67% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 15

18% more capital invested

Capital invested by funds: $326M → $386M (+$59.9M)

14% more funds holding

Funds holding: 71 → 81 (+10)

7.08% more ownership

Funds ownership: 84.87% → 91.96% (+7.1%)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
81
Holders Change
+10
Holders Change %
+14.08%
% of All Funds
1.07%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
25
Increased
27
Reduced
14
Closed
15
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$12.9M
2
Mercer Global Advisors
Mercer Global Advisors
Colorado
+$8.88M
3
DTC
Deep Track Capital
Connecticut
+$4.94M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$3.7M
5
Franklin Resources
Franklin Resources
California
+$3.05M

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$3.97M
2
JFG
Jefferies Financial Group
New York
-$3.54M
3
Morgan Stanley
Morgan Stanley
New York
-$3.33M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$3.29M
5
Goldman Sachs
Goldman Sachs
New York
-$1.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$63M +$570K +54,663 +1%
VA
2
VR Adviser
New York
$46.5M – – –
FFM
3
Fairmount Funds Management
Pennsylvania
$37.8M – – –
BlackRock
4
BlackRock
New York
$22.3M +$12.9M +1,241,206 +166%
RI
5
RTW Investments
New York
$21.8M – – –
DTC
6
Deep Track Capital
Connecticut
$21.5M +$4.94M +474,089 +33%
Vanguard Group
7
Vanguard Group
Pennsylvania
$20.4M +$1.87M +179,874 +11%
B
8
Braidwell
Connecticut
$17.1M -$496K -47,584 -3%
CC
9
Commodore Capital
New York
$15.9M – – –
Franklin Resources
10
Franklin Resources
California
$11.4M +$3.05M +292,421 +41%
PCH
11
Polar Capital Holdings
United Kingdom
$10.9M -$782K -75,000 -7%
Mercer Global Advisors
12
Mercer Global Advisors
Colorado
$9.55M +$8.88M +852,338 New
Blackstone Inc
13
Blackstone Inc
New York
$9.27M +$449K +43,071 +5%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$7.93M +$3.7M +354,821 +101%
AAA
15
Affinity Asset Advisors
New York
$6.76M +$606K +58,117 +11%
CCC
16
Cable Car Capital
California
$6.73M +$1.56M +150,000 +33%
FLSM
17
Frazier Life Sciences Management
California
$6.54M – – –
SOCM
18
SR One Capital Management
Pennsylvania
$4.82M – – –
T. Rowe Price Associates
19
T. Rowe Price Associates
Maryland
$4.61M -$7.51K -721 -0.2%
WP
20
Woodline Partners
California
$4.38M +$1.04K +100 +0%
State Street
21
State Street
Massachusetts
$4.18M +$2.98M +286,125 +330%
APM
22
Avidity Partners Management
Texas
$3.95M – – –
Point72 Asset Management
23
Point72 Asset Management
Connecticut
$3.7M -$129K -12,399 -4%
Northern Trust
24
Northern Trust
Illinois
$2.49M +$1.69M +162,593 +273%
Morgan Stanley
25
Morgan Stanley
New York
$2.34M -$3.33M -319,463 -61%
1
2 3 4

ORKA Hedge Fund Activity: Q2 2025 in Review

81 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2025, worth a combined $386M — up 18% from $326M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ORKA positions and 15 closed out — a net gain of 10 holders — while 27 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $12.9M. The largest seller was Redmile Group, exiting entirely with an estimated $3.97M sold.

  • 81 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2025, up from 71 in Q1 2025.
  • Funds reported $386M of Oruka Therapeutics stock for Q2 2025, up 18% quarter-over-quarter.
  • 25 funds opened new Oruka Therapeutics positions in Q2 2025 and 15 closed out, a net change of +10 holders.
  • The largest Oruka Therapeutics buyer in Q2 2025 was BlackRock, an estimated $12.9M added.
  • The largest Oruka Therapeutics seller in Q2 2025 was Redmile Group, an estimated $3.97M sold.

Based on aggregated 13F filings for Q2 2025.